<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Concentrations of 22 known <z:chebi fb="5" ids="17478">aldehydes</z:chebi> (byproducts of <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation), 5 acyloins, free and total <z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> and acylcarnitines were measured in plasma and urine obtained from pediatric patients with various forms of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> before any treatment, and following treatment with <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> or <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="5" ids="17478">Aldehydes</z:chebi>, before the initiation of chemotherapy, were significantly elevated in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients compared to controls </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="5" ids="17478">Aldehydes</z:chebi> such as hexanal, heptanal, and malondialdehyde were strikingly higher in samples from <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients, while trans 4-cis-4-decenal was the prominent <z:chebi fb="1" ids="17478">aldehyde</z:chebi> in the blood of controls </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, in each form of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> the pattern of <z:chebi fb="5" ids="17478">aldehydes</z:chebi> appeared to be unique when compared to controls, or to others forms of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients receiving chemotherapy there was a general trend toward a reduction 24 h after both the first and after the fifth <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> dose </plain></SENT>
<SENT sid="5" pm="."><plain>These changes however were not significant statistically due to large inter-patient variation </plain></SENT>
<SENT sid="6" pm="."><plain>Free and total plasma <z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> levels remained in the <z:mpath ids='MPATH_458'>normal</z:mpath> range, and there were no abnormal acylcarnitines detected in urine </plain></SENT>
<SENT sid="7" pm="."><plain>Possible hypotheses to explain the elevations in <z:chebi fb="5" ids="17478">aldehydes</z:chebi>, and the reasons for the changed <z:chebi fb="1" ids="17478">aldehyde</z:chebi> profiles in different forms of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> are discussed </plain></SENT>
</text></document>